The Fidelity MSCI Information Technology ETF (FTEC) offers broad passive exposure to nearly 300 U.S. tech stocks, maintaining appeal despite concerns about a shift to value investing. It projects a robust 28.84% earnings per share (EPS) growth next year and trades at a price-to-earnings ratio below its five-year average. While tech valuations could drop in a downturn, moderate compression combined with strong EPS growth is expected to still deliver healthy returns. This balance of risk and reward has led to a "buy" rating for FTEC, making it attractive for investors seeking quality tech sector exposure.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
